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Abstract
The SOD1G93A mouse has been used since 1994 for preclinical testing in amyotrophic lateral sclerosis (ALS). Despite recent
genetic advances in our understanding of ALS, transgenic mice expressing mutant SOD1 remain the best available, and
most widely used, vertebrate model of the disease. We previously described an optimised and rapid approach for preclinical
studies in the SOD1G93A mouse. Here we describe improvements to this approach using home cage running wheels to
obtain daily measurements of motor function, with minimal intervention. We show that home cage running wheels detect
reductions in motor function at a similar time to the rotarod test, and that the data obtained are less variable allowing the
use of smaller groups of animals to obtain satisfactory results. This approach refines use of the SOD1G93A model, and
reduces the number of animals undergoing procedures of substantial severity, two central principles of the 3Rs
(replacement, reduction and refinement of animal use in research). The small group sizes and rapid timescales enable
affordable large-scale therapeutic pre-screening in the SOD1G93A mouse, as well as rapid validation of published positive
effects in a second laboratory, one of the major stumbling blocks in ALS preclinical therapy development.
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Introduction
ALS is the most common adult onset neurodegenerative disease
affecting motor neurons. It is uniformly fatal, and there is only one
approved pharmacological treatment, Riluzole, which at best
extends survival by an average of only 3–4 months [1,2]. ALS is a
multi-factorial disease, and new treatments that target a range of
pathways are in preclinical development [3].
The standard in vivo model used for preclinical and proof of
concept studies in ALS is a transgenic mouse overexpressing a
human superoxide dismutase 1 minigene bearing a pathogenic
glycine to alanine mutation at amino acid position 93 (the
SOD1G93A mouse) [4]. It is clear that this is pathophysiologically a
valid model of ALS (since SOD1 mutations cause the disease in
humans), and it is known that the model has predictive validity
(since Riluzole, the only drug approved for human ALS patients
produces an increase in survival in SOD1G93A mice [5]). However,
despite these advantages, it is clear that the model is not perfect as
there have been a number of studies reporting beneficial effects of
drugs in SOD1G93A mice that have subsequently resulted in failure
in human trials. This problem was highlighted by a meta-analysis
that revealed a bias in the publication of positive preclinical results,
and significant shortcomings in experimental design in some of the
studies [6]. However multiple laboratories have generated mutant
SOD1 mice bearing different mutations, and the overt phenotype
of motor axonopathy leading to motor neuron death and
astrogliosis are very similar in each of these models, and compare
well with familial and sporadic forms of human ALS [7–9].
In recent years there has been an increase in translational
research conducted in academic settings. One reason for academic
involvement is the perception that Industry-led translational
medicine may be failing. This is because about 90% of drugs
that look promising in preclinical studies currently do not reach
the marketplace. The major reasons for this are lack of efficacy;
toxicity; and safety concerns [10]. In fact for central nervous
system (CNS) disorders the statistics are worse than this – only
about 1 in 20 drugs emerging from pre-clinical evaluation will
succeed in human trials.
As the number of animals being used for research continues to
rise, this must be weighed against the requirement to implement
the principles of the 3Rs (replacement, reduction and refinement
of animal use in research). For ALS mouse models, perhaps the
biggest opportunities are for refinement and reduction, since
progressive paralysis in end stage mice causes severe distress, and
large cohort sizes are required to obtain statistically valid results.
Previously, we proposed that earlier endpoints could be used
during early stage preclinical investigations in vivo, and described
a methodology that refined use of the SOD1G93A mouse model for
pre-clinical studies [11]. This approach resonates with several
studies that report a similar early reduction in motor performance
[12,13], and correlates with a loss of functional motor units as
measured by electromyography [14] and the onset of denervation
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of motor end-plates [15–17]. Here, we determine the efficacy of
home cage running wheels as an alternative early readout of motor
dysfunction in the SOD1G93A mouse model, and compare this to
current use of the rotarod in the same model. We show that home
cage running wheels can be used to detect motor dysfunction at an
early stage, and that running wheel data is inherently less variable
than that obtained using rotarod, thereby allowing refinement and
reduction in early-stage preclinical testing.
Methods
Ethics Statement
All experiments were conducted according to the Animal
(Scientific Procedures) Act 1986, under Project License 40/3089
reviewed and approved by the University of Sheffield Ethical
Review Sub-Committee, and the UK Animal Procedures Com-
mittee (London, UK). The UK Home Office code of practice for
the housing and care of animals used in scientific procedures was
followed. We adhere to the ARRIVE guidelines for reporting
animal research [18].
Transgenic C57BL/6 SOD1G93A model of ALS
As previously described [11], we use a congenic strain of
transgenic C57BL/6 SOD1G93A mice which were originally
obtained from the Jackson Laboratory [4], and hemizygous
transgenic males were backcrossed to C57BL/6 females (Harlan
UK, C57BL/6 J OlaHsd substrain) for .20 generations.
Transgenic SOD1G93A mice were identified by ear biopsy and
PCR as previously described [11]. Transgene copy number was
routinely determined using quantitative PCR [11]. The humane
endpoint used in our experiments is loss of self-righting ability
within 10 seconds of being placed on the back, or weight loss of .
30% for 72 hours. Mice were provided with wet mashed food in
their cages at the first sign of hind limb paralysis. At this point the
cage bedding material was changed to paper towel to reduce dust
and allow for easier locomotion.
Housing
Mice were bred in a specified pathogen free (SPF) environment,
and transferred to a conventional facility for the studies described
here. The facility uses a 12 h light/dark cycle, and a standardised
room temperature of 21uC. Mice were fed 2018 rodent diet
(Harlan, UK) ad libitum. Cages were lined with fine sawdust (eco-
pure chips premium). Paper wool (Datesand, UK) was used as
bedding material, and plastic houses were provided in each cage.
Study Design
We followed principles of experimental design in line with
published recommendations [19]. Based on our previous studies,
we required groups of at least 14 mice to achieve appropriate
power for rotarod analysis, and up to 15 mice per group for
survival analysis [11]. Since one purpose of this study was a direct
comparison with existing methods, we chose to use groups of 15
mice. Previous studies have demonstrated that wild type female
C57BL/6 mice show a greater propensity for spontaneous home
cage running wheel activity [20], therefore we used single-sex
experimental cohorts of female mice. It should be noted that on
the C57BL/6 background we find no differences in disease onset,
progression or lifespan in male and female mice [11].
Between 26 and 32 days of age, litter-matched SOD1G93A mice
were randomly assigned to one of two experimental groups. The
first group were housed individually in 36621618.5 cm (length6
width 6 height) cages with a Fast Trac running wheel (LBS
Biotech, UK) 37.8 cm circumference, fitted on the underside with
a 5610 mm neodymium magnet (First4magnets.com), and
mounted at a height of 4 cm on a lubricated axle at an angle of
25u below horizontal. Almost identical wheels are also available in
the USA e.g. Inno Wheel (Bio-Serv, USA). The wheel was
positioned so that it is at a distance of 5–10 mm from the sides of
the cage. Voluntary running wheel activity was monitored using a
reed switch coupled to a bicycle odometer (Cateye Velo series)
(Figure 1). This experimental set-up is based on that previously
described for experiments investigating the effects of exercise
training in mice [20]. The second group were housed in identical
cages, but with a Fast Trac wheel that did not rotate.
Additional preclinical studies were performed as described in
Table 1. Data obtained from placebo cohorts were analysed to
determine the reliability of running wheel data between experi-
ments. Group sizes vary depending on whether the studies were
powered for survival or running wheel endpoints.
Behavioural Measures
Wheel running activity was recorded every morning, and
subsequently adjusted for the circumference of the running wheel.
Distance (km) was recorded as the total number of wheel
revolutions multiplied by the circumference. Time (hours) was
recorded as continuous wheel activity, with a maximum gap of 5 s
between rotations. Average speed (km/h) is calculated as the total
distance divided by the time for a 24 h period. Maximum speed is
the highest recorded running speed in a 24 h period. Because the
bedding material was often found to be wrapped around the wheel
support, Fast Trac wheels and odometers were checked every
morning to ensure the wheels were freely rotating, and the reed
switches were functional. Very occasionally data points were
censored because of jammed wheels caused by bedding material,
an odometer that failed to reset, a detached reed switch, or a water
bottle leak. Across all studies presented here we censored on
average just 0.23 days per mouse.
A Ugo Basile 7650 accelerating rotarod (set to accelerate from
4–40 rpm over 300 seconds) was used to measure motor function.
Rotarod training was performed over 3 consecutive days, with two
trials per day. Subsequently this test was performed at weekly
intervals during the afternoon. On each occasion the mice were
tested twice, with a rest period between runs. The best
performance, measured as latency to fall in seconds, was used
for analysis. The minimum threshold for recording rotarod activity
was 5 seconds. For analysis of disease onset and progression we
calculated the time at which individual mice reached a 20%
Figure 1. A typical cage set-up for assessment of home cage
running activity. The angled Fast Trac running wheel is located such
that the magnet is sufficiently close to the reed switch positioned on
the exterior of the cage.
doi:10.1371/journal.pone.0107918.g001
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decline in rotarod performance, compared to their specific post-
training baseline.
Body weight was determined at weekly intervals until 120 days
of age, at which point SOD1G93A mice were weighed daily to
monitor mice for signs of severe disease-associated weight loss.
Mice were also scored for tremor, hind-limb splay and overall
neurological deficit using a previously reported scoring system
[11]. Disease onset was defined as the point at which both
enhanced tremor and defective hind-limb splay were first
observed. From 125 days of age SOD1G93A mice were monitored
twice daily using a distress scoring system [11], until they reached
the humane endpoint for euthanasia (see above). At this point mice
were euthanized with an overdose of anaesthetic (intraperitoneal
injection of 20 ml/kg pentobarbitone).
Statistics
Prism 6.0 (GraphPad Software Inc) was used for statistical
analysis. Details of specific tests are stated in the text. G*Power 3.1
was used for all power calculations [21].
Results
Validation of home cage running wheels in female
C57BL/6 J OlaHsd mice
We first investigated Fast Trac running wheel activity in a
cohort of 15 C57BL/6 J OlaHsd female mice, beginning at 6
weeks of age. These are the same C57BL/6 substrain as our
SOD1G93A mouse colony [11]. The typical home cage set-up is
shown in Figure 1. Data for running time, distance, maximum
speed and average speed were recorded daily for 130 days
(Figure 2A–D). As previously reported, the mice showed an
increase in activity over the first few weeks, and then stabilise at a
plateau of activity thereafter. It is notable that, unlike previous
studies [20,22], we show a gradual decline in time spent running
(Figure 2A) and distance run (Figure 2B) over the prolonged
period of investigation, whereas average and maximum speed
remain relatively consistent (Figure 2C–D). The days on which
peak activity was recorded, and mean performance (6SD) after
that day were as follows: Time spent running: peak day 29, mean
during plateau phase 5.0660.70 hours/day. Distance run: peak
day 31, mean during plateau phase 15.0761.78 km/day. Average
and maximum speeds do not reach a peak until day 114 and 120
respectively, suggesting that these parameters continue to improve
over time. Our results are comparable with previous investigations
[20,22], and suggest that C57BL/6 J OlaHsd substrain mice are
suitable for the proposed study.
Early read outs of motor dysfunction
To establish whether home cage running wheels allowed earlier
detection of motor dysfunction, we investigated Fast Trac wheel-
running in a cohort of 15 female SOD1G93A mice. Because we
previously showed a 20% reduction in rotarod performance in
these mice at approximately 50 days of age, we placed mice in
cages with running wheels as soon as possible following weaning,
genotyping and transfer from SPF housing to the conventional
facility. This varied between 25 and 31 days old. The graphs in
Figure 3 show data collected from 28 days onwards, the point at
which 50% of the cohort had been recruited. The time, distance
and average speed of running wheel activity in the SOD1G93A
mice increases until approximately 40 days of age, when these
parameters begin to decline until a plateau is reached at 60 days
old. A further decrease in time, distance and average speed is
observed between 100 and 130 days, at which point SOD1G93A
mice cease running. It is interesting to note that maximum
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running speed remains in the range of 2.8–3.5 km/h until mice
are 120 days old.
We previously showed that the time taken for a 20% reduction
in latency to fall from the rotarod could be used as an easy to
implement early readout of motor dysfunction in SOD1G93A mice
[11]. We calculated the mean age at which the distance run, time
spent running and average speed of each mouse showed a 20%
reduction. For distance run this was 44.363.3 days, for time spent
Figure 2. Running wheel activity of wild type C57BL/6 J OlaHsd mice. Mean (6 SD) time (A), distance (B), maximum speed (C) and average
speed (D) were recorded for 130 days in a group of 15 mice, starting at 6 weeks of age.
doi:10.1371/journal.pone.0107918.g002
Figure 3. Running wheel activity of SOD1G93A mice. Mean (6 SD) time (A), distance (B), maximum speed (C) and average speed (D) were
recorded in a group of 15 mice, starting from 25–31 days of age. Data are plotted from 28 days onwards, until the mice no longer used the running
wheels.
doi:10.1371/journal.pone.0107918.g003
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running it was 45.564.5 days, and for average speed it was
47.163.8 days. Each of these is similar to the ages at which we
previously reported a reduction of similar magnitude in rotarod
performance (47.0 to 58.3 days) [11]. Interestingly, distance run
(p,0.01) and time spent running (p,0.05) both detected a 20%
decline in performance at an earlier stage than average speed
(Kruskal-Wallis with Dunn’s multiple comparisons test). In
Figure 4D onset determined as a 20% reduction in running wheel
activity is presented.
Impact of wheel running on disease course
There are conflicting reports that voluntary exercise might
influence the disease course in mutant SOD1 mouse models. To
determine the effect of home cage voluntary running activity on
disease course, in parallel to the above experiment we also housed
transgenic female SOD1G93A mice in identical cages, with non-
rotating wheels. To control for litter effects, we used littermates of
the SOD1G93A mice on running wheels.
Mice from both cohorts (i.e. with and without running wheels)
were tested weekly on an accelerating rotarod (Figure 4A). There
was a clear improvement in rotarod performance in the mice with
access to running wheels (Two-way ANOVA p,0.0001), although
the same pattern of disease progression (early decline, plateau, and
final decline in performance) was seen in both groups. This pattern
correlates with the pathology that has been previously described in
the SOD1G93A model, with fast fatigable motor neuron endplates
dying-back prior to symptom onset, fast non-fatigable endplates
dying-back at onset, and slow endplates showing resistance [17].
The age at which we first observed a 20% reduction in rotarod
performance was 55.169.1 days in non-running mice and
65.8611.1 days in the running group. This was a significant
difference (unpaired t test: p,0.01), suggesting a beneficial effect
of wheel-running in this context. The data is also presented as a
survival curve to allow direct comparison of onset between groups
and between experiments (Figure 4C).
Mice were weighed weekly, and although there was no
significant difference in peak body weight (15.960.7 g in non-
running mice and 15.860.7 g in the running group), the age at
which mice reached peak body weight was significantly later in the
running-wheel group (64.4622.0 days in non-running mice and
91.0616.1 days in the running group. Mann-Whitney test: p,
0.01).
Mice were scored weekly for disease onset defined by the age at
which abnormal hindlimb splay and tremor were both observed.
Using these criteria, onset was very similar in both groups:
77.667.1 in non-running mice and 78.6610.1 in the running
group (Mann-Whitney test: non-significant). Finally we deter-
mined the survival of both groups, defined as the point at which
mice were unable to self-right within 10 seconds of being placed on
the back. Using the Log-rank (Mantel-Cox) test there was no
significant difference between running and non-running groups
(Figure 4B).
Running wheels provide a very reliable measure of
disease onset
To determine whether home cage running wheel activity is a
reliable readout of early motor dysfunction we analysed the data
obtained from control groups used in 6 therapeutic studies run
over an 18 month period (Table 1). The running wheel data for
the 6 groups are shown in Figure 5. The results are highly
reproducible between studies, and the average ages at which a
20% reduction in running wheel activity is observed are
summarised in Table 1. Importantly each study shows a low
coefficient of variation (CV), and analysis of all 72 mice
investigated to date allows us to determine the CV to be as low
as 9.0% for distance run and average speed. When considering the
mean data obtained in each of the experiments, the ‘‘between
Figure 4. The effect of home cage running wheels on disease course in SOD1G93A mice. Graphs showing rotarod (A), survival (B), onset
determined by a 20% reduction in rotarod performance (C), and onset determined by a 20% decrease in running wheel activity (D) in littermate
SOD1G93A mice either with or without access to a home cage running wheel. In A–C mice with access to running wheels are shown in purple. In D
onset determined by a 20% decline in the distance run is shown in red, time spent running is shown in blue and average speed is shown in black.
doi:10.1371/journal.pone.0107918.g004
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study’’ CV is between 2.2 and 3.8% for the running wheel
parameters. Using the mean and standard deviation of these 72
mice we have calculated that using treatment and control groups
of 4 mice provides 80% power to detect a 10 day difference in the
age at which a 20% reduction in distance run is observed (groups
of 5 are powered to detect a 10 day difference in time spent
running and average speed). This is a dramatic reduction in the
number of animals required when compared to rotarod, which
requires 14 mice per group for the same reduction compared to
peak performance [11].
Discussion
Animal models are essential for understanding disease mecha-
nisms and developing treatments for ALS. We are fortunate that
the SOD1G93A mouse is a well-established model of ALS, with a
widely accepted set of guidelines for use in preclinical studies
[23,24]. Despite this, the model can be refined to further enhance
its usefulness. For instance, therapeutic studies using survival as an
endpoint take 140 days to complete, which is significant in terms of
cost and personnel. Also the welfare of SOD1G93A mice is a serious
concern, particularly in the latter stages of the disease. Thus it is
desirable to refine the model to be able to use earlier endpoints.
It is now accepted that the earliest symptoms of ALS in human
patients involve dying back of axons, and subsequent remodelling
of neuromuscular junctions [15,25]. SOD1G93A mice mimic this
early neuromuscular pathology faithfully, and we can use
quantitative measurements of muscle weakness such as rotarod,
grip-strength and wheel-running to follow the progressive deteri-
oration of neuromuscular junctions during the disease course. It is
rarely possible to measure the earliest stages of ALS in human
patients using the same quantitative approach. However a
prospective 3 year long study of presymptomatic SOD1 mutation
carriers, two sisters with V148G SOD1 mutations both showed
significant loss of abductor pollicis brevis motor units using
MUNE, 6 months before alterations in grip strength were reported
[26].
We previously showed that reductions in rotarod performance
could be used as an early endpoint in SOD1G93A mice [11].
However the rotarod has a number of disadvantages. The data are
quite variable, which necessitates the use of 14 mice per group
(therefore 28 in total for placebo and treatment groups). The test is
artificial, involves forced activity and testing takes place during the
daytime, when mice are normally sleeping. Rotarod testing is also
time consuming for the investigator, especially if data are to be
collected several times per week for each mouse. In the current
investigation we compared the use of rotarod with home cage
running wheels. In contrast to rotarod, this use of home cage
running wheels is a voluntary activity, takes place during the night
when mice are most active, and produces data every day for each
mouse with minimal intervention and investigator involvement.
We show that, like the rotarod, home cage running wheels allow us
to detect an early reduction in motor performance. We are able to
detect a 20% reduction in performance with reduced variability,
when compared to rotarod. Therefore we are able to reduce the
timescale of early readout studies to 60 days, and also reduce the
number of mice used by.60%, to 4 per group (therefore 8 in total
for placebo and treatment groups). Over this time course the mice
show no classical signs of disease, obvious gait abnormalities or
distress compared to non-transgenic littermates [11]. However, as
we and others have demonstrated previously, this early decline in
motor performance correlates with the loss of NMJ integrity in
hindlimb muscles [11,14–17]. As such it is a proxy for EMG
recordings, which are the gold standard method for measuring
motor units in mice and human ALS patients. However EMG is
not suitable for daily testing in mice, so alternative approaches,
such as running wheel activity, are a useful way of obtaining
similar results.
The main goal of preclinical experiments is to increase lifespan,
indeed this is the principal endpoint in human ALS clinical trials.
Therefore we propose that early endpoints should not be seen as a
complete replacement for preclinical survival studies. For individ-
ual therapeutic approaches we will still need to empirically
determine whether changes in the early readouts will lead to
changes at the later stages of disease. Survival studies are also
important because the majority of clinical trials in ALS patients
use survival at 12 or 18 months as the primary endpoint [1].
However, the small group sizes and rapid timescales permitted by
use of running wheels do facilitate affordable large-scale thera-
peutic pre-screening in the SOD1G93A mouse, as well as rapid
validation of published positive effects in a second laboratory, one
of the requirements for preclinical screening for ALS set out in the
current guidelines [24]. Therapeutic agents that show significant
improvements in running wheel activity could then be validated in
a secondary survival study over a longer time-frame.
One interesting finding in this study was the effect of home cage
running wheels on disease course in SOD1G93A mice. The impact
of exercise in ALS has been somewhat controversial. We found
that voluntary running activity did not affect onset (defined by
appearance of tremor and hindlimb splay defect) or survival in
female SOD1G93A mice. However, it did significantly modify the
temporal nature of weight gain in the mice, and significantly
improved the performance of SOD1G93A mice on the rotarod.
Previously it was reported that male, but not female C57BL/6
mice, given access to the same Fast Trac running wheels had a
reduced weight after 5 weeks of exercise [20]. In keeping with this,
after 5 weeks of exercise our female SOD1G93A mice did not show
a significant difference in weight compared to non-running
SOD1G93A littermates (data not shown). We are not able to
explain the beneficial effects of running wheel activity on rotarod
performance, beyond the possibility that this may reflect a training
effect in the mice that exercise regularly. We previously showed
that in female C57BL/6 mice home cage running wheels altered
the transcriptome in both hindlimb muscles and spinal cord motor
neurons [22]. It would be interesting to investigate whether any of
the pathways identified by changes in gene expression, such as
axon branching in motor neurons, or neovascularisation and
myogenesis in muscle, are associated with the improvement in
rotarod performance we report in exercised SOD1G93A mice.
However on balance, we are cautious about over-interpretation of
this effect, since there was no improvement of overall survival in
the mice with access to running wheels.
We also predict the usefulness of this approach in other settings,
including new mouse models of ALS. New animal models of ALS
are needed to understand disease mechanisms and therapeutics,
and the discovery of new genes causing familial ALS mean that
new models are likely to emerge in the next few years. However,
despite the excitement in the ALS field surrounding TDP-43
mutations and the prevalence of TDP-43 as a pathological marker
in ALS [27], there is no consensus opinion yet for a robust and
useful animal model of TDP-43 related ALS that closely mimics
the human disease [28].
In conclusion we present a method for very rapid, sensitive, and
reliable measurement of motor dysfunction in SOD1G93A mice,
which offers significant advantages for refinement and reduction of
animal use in ALS preclinical testing.
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